B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

PDE5A

MOLECULAR TARGET

phosphodiesterase 5A

UniProt: O76074NCBI Gene: 865424 compounds

PDE5A (phosphodiesterase 5A) is targeted by 24 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting PDE5A

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1rolipram5.12166
2sb 2035804.92136
3ly 2940024.84126
4sildenafil4.78118
5alpha naphthoflavone4.67106
6milrinone4.3980
7palbociclib4.2267
8dipyridamole4.0355
9tadalafil3.9350
10zaprinast3.8144
11isobutylmethylxanthine3.7140
12beta ccm3.2625
13vardenafil3.1823
14fpl 557123.1823
15rutaecarpine3.0921
16pptn2.8917
17cilostamide2.5612
18ibudilast2.4811
19sophoraflavanone b2.4811
20icaritin2.4010
21bw a78u1.956
22Sildenafil Citrate1.393
23Epimedium0.691
24Papaverine0.691

About PDE5A as a Drug Target

PDE5A (phosphodiesterase 5A) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 24 compounds with documented PDE5A interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

PDE5A inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.